The reversal of antineoplastic drug resistance in cancer cells by 尾-elemene

详细信息    查看全文

• 作者：Guan-Nan Zhang ; Charles R. Ashby Jr. ; Yun-Kai Zhang…
• 关键词：Rhizoma zedoariae ; 尾 ; Elemene ; Multidrug resistance
• 刊名：Chinese Journal of Cancer
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：34
• 期：3
• 全文大小：1260KB
• 参考文献：1.Lim CB, Ky N, Ng HM, Hamza MS, Zhao Y. Curcuma wenyujin extract induces apoptosis and inhibits proliferation of human cervical cancer cells in vitro and in vivo. Integr Cancer Ther. 2010;9(1):36鈥?9. doi:10.鈥?177/鈥?534735409359773鈥?/span> .CrossRef PubMed
  2.Lai EY, Chyau CC, Mau JL, Chen CC, Lai YJ, Shih CF, et al. Antimicrobial activity and cytotoxicity of the essential oil of Curcuma zedoaria. Am J Chin Med. 2004;32(2):281鈥?0. doi:10.鈥?142/鈥婼0192415X0400193鈥媂 .CrossRef PubMed
  3.Tohda C, Nakayama N, Hatanaka F, Komatsu K. Comparison of anti-inflammatory activities of six Curcuma rhizomes: a possible curcuminoid-independent pathway mediated by Curcuma phaeocaulis extract. Evid Based Complement Alternat Med. 2006;3(2):255鈥?0. doi:10.鈥?093/鈥媏cam/鈥媙el008 .PubMed Central CrossRef PubMed
  4.Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. Multiple biological activities of curcumin: a short review. Life Sci. 2006;78(18):2081鈥?. doi:10.鈥?016/鈥媕.鈥媗fs.鈥?005.鈥?2.鈥?07 .CrossRef PubMed
  5.Makabe H, Maru N, Kuwabara A, Kamo T, Hirota M. Anti-inflammatory sesquiterpenes from Curcuma zedoaria. Nat Prod Res. 2006;20(7):680鈥?. doi:10.鈥?080/鈥?478641050046290鈥? .CrossRef PubMed
  6.Park SD, Jung JH, Lee HW, Kwon YM, Chung KH, Kim MG, et al. Zedoariae rhizoma and curcumin inhibits platelet-derived growth factor-induced proliferation of human hepatic myofibroblasts. Int Immunopharmacol. 2005;5(3):555鈥?9. doi:10.鈥?016/鈥媕.鈥媔ntimp.鈥?004.鈥?1.鈥?03 .CrossRef PubMed
  7.Zhang J, Zhang H, Chen L, da Sun W, Mao C, Chen W, et al. 尾-Elemene reverses chemoresistance of breast cancer via regulating MDR-related microRNA expression. Cell Physiol Biochem. 2014;34(6):2027鈥?7. doi:10.鈥?159/鈥?00366398 .CrossRef PubMed
  8.Lee RX, Li QQ, Reed E. 尾-Elemene effectively suppresses the growth and survival of both platinum-sensitive and -resistant ovarian tumor cells. Anticancer Res. 2012;32(8):3103鈥?3.PubMed Central PubMed
  9.Zheng S, Yang H, Zhang S, Wang X, Yu L, Lu J, et al. Initial study on naturally occurring products from traditional Chinese herbs and vegetables for chemoprevention. J Cell Biochem Suppl. 1997;27:106鈥?2.CrossRef PubMed
  10.Zhou HY, Shen JK, Hou JS, Qiu YM, Luo QZ. Experimental study on apoptosis induced by elemene in glioma cells. Ai Zheng. 2003;22(9):959鈥?3 (in Chinese).PubMed
  11.Wang G, Li X, Huang F, Zhao J, Ding H, Cunningham C, et al. Antitumor effect of beta-elemene in non-small-cell lung cancer cells is mediated via induction of cell cycle arrest and apoptotic cell death. Cell Mol Life Sci. 2005;62(7鈥?):881鈥?3. doi:10.鈥?007/鈥媠00018-005-5017-3 .CrossRef PubMed
  12.Li X, Wang G, Zhao J, Ding H, Cunningham C, Chen F, et al. Antiproliferative effect of beta-elemene in chemoresistant ovarian carcinoma cells is mediated through arrest of the cell cycle at the G2-M phase. Cell Mol Life Sci. 2005;62(7鈥?):894鈥?04. doi:10.鈥?007/鈥媠00018-005-5027-1 .CrossRef PubMed
  13.Zhao J, Li QQ, Zou B, Wang G, Li X, Kim JE, et al. In vitro combination characterization of the new anticancer plant drug beta-elemene with taxanes against human lung carcinoma. Int J Oncol. 2007;31(2):241鈥?2.PubMed
  14.Li QQ, Wang G, Zhang M, Cuff CF, Huang L, Reed E. beta-Elemene, a novel plant-derived antineoplastic agent, increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis. Oncol Rep. 2009;22(1):161鈥?0.CrossRef PubMed
  15.Kishi S, Ueda T. Chemotherapy. Nihon Rinsho. 2014;72(3):462鈥? (in Japanese).PubMed
  16.Gottesman MM. How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 1993;53(4):747鈥?4.PubMed
  17.Gillet JP, Gottesman MM. Mechanisms of multidrug resistance in cancer. Methods Mol Biol. 2010;596:47鈥?6. doi:10.鈥?007/鈥?78-1-60761-416-6_鈥? .CrossRef PubMed
  18.Seitz G, Bonin M, Fuchs J, Poths S, Ruck P, Warmann SW, et al. Inhibition of glutathione-S-transferase as a treatment strategy for multidrug resistance in childhood rhabdomyosarcoma. Int J Oncol. 2010;36(2):491鈥?00.PubMed
  19.Lewis AD, Forrester LM, Hayes JD, Wareing CJ, Carmichael J, Harris AL, et al. Glutathione S-transferase isoenzymes in human tumours and tumour derived cell lines. Br J Cancer. 1989;60(3):327鈥?1.PubMed Central CrossRef PubMed
  20.Reed JC. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol. 1995;7(6):541鈥?.CrossRef PubMed
  21.van Veen HW, Konings WN. The ABC family of multidrug transporters in microorganisms. Biochim Biophys Acta. 1998;1365(1鈥?):31鈥?.CrossRef PubMed
  22.Wang B, Peng XX, Sun R, Li J, Zhan XR, Wu LJ, et al. Systematic review of beta-elemene injection as adjunctive treatment for lung cancer. Chin J Integr Med. 2012;18(11):813鈥?3. doi:10.鈥?007/鈥媠11655-012-1271-9 .CrossRef PubMed
  23.Roninson IB, Chin JE, Choi KG, Gros P, Housman DE, Fojo A, et al. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA. 1986;83(12):4538鈥?2.PubMed Central CrossRef PubMed
  24.Van der Bliek AM, Baas F, Ten Houte de Lange T, Kooiman PM, Van der Velde-Koerts T, Borst P. The human mdr3 gene encodes a novel P-glycoprotein homologue and gives rise to alternatively spliced mRNAs in liver. EMBO J. 1987;6(11):3325鈥?1.PubMed Central PubMed
  25.de Bruijn MH, Van der Bliek AM, Biedler JL, Borst P. Differential amplification and disproportionate expression of five genes in three multidrug-resistant Chinese hamster lung cell lines. Mol Cell Biol. 1986;6(12):4717鈥?2.PubMed Central PubMed
  26.Gros P, Raymond M, Bell J, Housman D. Cloning and characterization of a second member of the mouse mdr gene family. Mol Cell Biol. 1988;8(7):2770鈥?.PubMed Central PubMed
  27.Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992;258(5088):1650鈥?.CrossRef PubMed
  28.Guo Y, Kotova E, Chen ZS, Lee K, Hopper-Borge E, Belinsky MG, et al. MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2鈥?3鈥?dideoxycytidine and 9鈥?(2鈥?phosphonylmethoxyethyl)adenine. J Biol Chem. 2003;278(32):29509鈥?4. doi:10.鈥?074/鈥媕bc.鈥婱304059200 .CrossRef PubMed
  29.Robert J, Jarry C. Multidrug resistance reversal agents. J Med Chem. 2003;46(23):4805鈥?7. doi:10.鈥?021/鈥媕m030183a .CrossRef PubMed
  30.Krishna R, Mayer LD. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors. Cancer Res. 1997;57(23):5246鈥?3.PubMed
  31.Wu CP, Calcagno AM, Ambudkar SV. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol. 2008;1(2):93鈥?05.PubMed Central CrossRef PubMed
  32.Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981;41(5):1967鈥?2.PubMed
  33.Ozols RF, Cunnion RE, Klecker RW Jr, Hamilton TC, Ostchega Y, Parrillo JE, et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol. 1987;5(4):641鈥?.PubMed
  34.Dantzig AH, de Alwis DP, Burgess M. Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv Drug Deliv Rev. 2003;55(1):133鈥?0.CrossRef PubMed
  35.Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Potentiation of vincristine and adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res. 1983;43(5):2267鈥?2.PubMed
  36.Shukla S, Chen ZS, Ambudkar SV. Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. Drug Resist Updat. 2012;15(1鈥?):70鈥?0. doi:10.鈥?016/鈥媕.鈥媎rup.鈥?012.鈥?1.鈥?05 .PubMed Central CrossRef PubMed
  37.Boesch D, Muller K, Pourtier-Manzanedo A, Loor F. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp Cell Res. 1991;196(1):26鈥?2.CrossRef PubMed
  38.Germann UA, Shlyakhter D, Mason VS, Zelle RE, Duffy JP, Galullo V, et al. Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs. 1997;8(2):125鈥?0.CrossRef PubMed
  39.Filipski E, Berland E, Ozturk N, Guettier C, van der Horst GT, Levi F, et al. Optimization of irinotecan chronotherapy with P-glycoprotein inhibition. Toxicol Appl Pharmacol. 2014;274(3):471鈥?. doi:10.鈥?016/鈥媕.鈥媡aap.鈥?013.鈥?2.鈥?18 .CrossRef PubMed
  40.Aouali N, El Btaouri H, Dumontet C, Eddabra L, Malagarie-Cazenave S, Madoulet C, et al. Accumulation of lactosylceramide and overexpression of a PSC833-resistant P-glycoprotein in multidrug-resistant human sarcoma cells. Oncol Rep. 2011;25(4):1161鈥?. doi:10.鈥?892/鈥媜r.鈥?011.鈥?180 .PubMed
  41.Lhomme C, Joly F, Walker JL, Lissoni AA, Nicoletto MO, Manikhas GM, et al. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J Clin Oncol. 2008;26(16):2674鈥?2. doi:10.鈥?200/鈥婮CO.鈥?007.鈥?4.鈥?807 .CrossRef PubMed
  42.Muller H, Pajeva IK, Globisch C, Wiese M. Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem. 2008;16(5):2448鈥?2. doi:10.鈥?016/鈥媕.鈥媌mc.鈥?007.鈥?1.鈥?57 .CrossRef PubMed
  43.Morschhauser F, Zinzani PL, Burgess M, Sloots L, Bouafia F, Dumontet C. Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar. 3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin鈥檚 lymphoma. Leuk Lymphoma. 2007;48(4):708鈥?5. doi:10.鈥?080/鈥?042819070119016鈥? .CrossRef PubMed
  44.van Zuylen L, Sparreboom A, van der Gaast A, Nooter K, Eskens FA, Brouwer E, et al. Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933. Eur J Cancer. 2002;38(8):1090鈥?.CrossRef PubMed
  45.Guns ES, Bullock PL, Reimer ML, Dixon R, Bally M, Mayer LD. Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes. Eur J Drug Metab Pharmacokinet. 2001;26(4):273鈥?2.CrossRef PubMed
  46.Kim TE, Lee H, Lim KS, Lee S, Yoon SH, Park KM, et al. Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers. Br J Clin Pharmacol. 2014;. doi:10.鈥?111/鈥媌cp.鈥?2368 .
  47.Karikas GA. Anticancer and chemopreventing natural products: some biochemical and therapeutic aspects. J BUON. 2010;15(4):627鈥?8.PubMed
  48.Guo H, Wang DS, Rizwani GH, Ahmed M, Ahmed M, Hassan A, et al. Antineoplastic activity of Holoptelea integrifolia (Roxb.) Planch bark extracts (in vitro). Pak J Pharm Sci. 2013;26(6):1151鈥?.PubMed
  49.Guo HQ, Zhang GN, Wang YJ, Zhang YK, Sodani K, Talele TT, et al. beta-Elemene, a compound derived from Rhizoma zedoariae, reverses multidrug resistance mediated by the ABCB1 transporter. Oncol Rep. 2014;31(2):858鈥?6. doi:10.鈥?892/鈥媜r.鈥?013.鈥?870 .PubMed
  50.Lu JJ, Dang YY, Huang M, Xu WS, Chen XP, Wang YT. Anticancer properties of terpenoids isolated from Rhizoma Curcumae鈥攁 review. J Ethnopharmacol. 2012;143(2):406鈥?1. doi:10.鈥?016/鈥媕.鈥媕ep.鈥?012.鈥?7.鈥?09 .CrossRef PubMed
  51.Liu J, Zhang Y, Qu J, Xu L, Hou K, Zhang J, et al. beta-Elemene-induced autophagy protects human gastric cancer cells from undergoing apoptosis. BMC Cancer. 2011;11:183. doi:10.鈥?186/鈥?471-2407-11-183 .PubMed Central CrossRef PubMed
  52.Yao YQ, Xu YH, Lu J, Zhou HY, Wang YZ. Effect of p38 MAPK on elemene-induced cell cycle arrest in C6 glioblastoma cells. Zhonghua Yi Xue Za Zhi. 2008;88(1):56鈥? (in Chinese).PubMed
  53.Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer. 2005;5(3):231鈥?. doi:10.鈥?038/鈥媙rc1560 .PubMed
  54.Guo B, Zhai D, Cabezas E, Welsh K, Nouraini S, Satterthwait AC, et al. Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature. 2003;423(6938):456鈥?1. doi:10.鈥?038/鈥媙ature01627 .CrossRef PubMed
  55.Chaudhry P, Srinivasan R, Patel FD. Differential expression of Fas family members and Bcl-2 family members in benign versus malignant epithelial ovarian cancer (EOC) in North Indian population. Mol Cell Biochem. 2012;368(1鈥?):119鈥?6. doi:10.鈥?007/鈥媠11010-012-1350-7 .CrossRef PubMed
  56.Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994;9(6):1799鈥?05.PubMed
  57.Chen X, Wang Y, Luo H, Luo Z, Zhang T, Yang N, et al. beta-Elemene acts as an antitumor factor and downregulates the expression of survivin, Bcl-xL and Mta-1. Mol Med Rep. 2012;6(5):989鈥?5. doi:10.鈥?892/鈥媘mr.鈥?012.鈥?018 .PubMed
  58.Li QQ, Wang G, Huang F, Banda M, Reed E. Antineoplastic effect of beta-elemene on prostate cancer cells and other types of solid tumour cells. J Pharm Pharmacol. 2010;62(8):1018鈥?7. doi:10.鈥?111/鈥媕.鈥?042-7158.鈥?010.鈥?1135.鈥媥 .CrossRef PubMed
  59.Zhao S, Wu J, Zheng F, Tang Q, Yang L, Li L, et al. beta-Elemene inhibited expression of DNA methyltransferase 1 through activation of ERK1/2 and AMPKalpha signalling pathways in human lung cancer cells: the role of Sp1. J Cell Mol Med. 2015;19(3):630鈥?1. doi:10.鈥?111/鈥媕cmm.鈥?2476 .PubMed Central CrossRef PubMed
  60.Li G, Xie B, Li X, Chen Y, Xu Y, Xu-Welliver M, et al. Downregulation of peroxiredoxin-1 by beta-elemene enhances the radiosensitivity of lung adenocarcinoma xenografts. Oncol Rep. 2015;33(3):1427鈥?3. doi:10.鈥?892/鈥媜r.鈥?015.鈥?732 .PubMed
  61.Xu HB, Li L, Fu J, Mao XP, Xu LZ. Reversion of multidrug resistance in a chemoresistant human breast cancer cell line by beta-elemene. Pharmacology. 2012;89(5鈥?):303鈥?2. doi:10.鈥?159/鈥?00337178 .CrossRef PubMed
  62.Gottlieb E, Armour SM, Harris MH, Thompson CB. Mitochondrial membrane potential regulates matrix configuration and cytochrome c release during apoptosis. Cell Death Differ. 2003;10(6):709鈥?7. doi:10.鈥?038/鈥媠j.鈥媍dd.鈥?401231 .CrossRef PubMed
  63.Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74(6):957鈥?7.CrossRef PubMed
  64.Sui X, Kong N, Ye L, Han W, Zhou J, Zhang Q, et al. p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents. Cancer Lett. 2014;344(2):174鈥?. doi:10.鈥?016/鈥媕.鈥媍anlet.鈥?013.鈥?1.鈥?19 .CrossRef PubMed
  65.Elias J, Dimitrio L, Clairambault J, Natalini R. The p53 protein and its molecular network: modelling a missing link between DNA damage and cell fate. Biochim Biophys Acta. 2014;1844(1 Pt B):232鈥?7. doi:10.鈥?016/鈥媕.鈥媌bapap.鈥?013.鈥?9.鈥?19 .CrossRef PubMed
  66.Saha MN, Qiu L, Chang H. Targeting p53 by small molecules in hematological malignancies. J Hematol Oncol. 2013;6:23. doi:10.鈥?186/鈥?756-8722-6-23 .PubMed Central CrossRef PubMed
  67.Wang JQ, Du ZW, Gao XF, Wu M, Zhang YC, Pan Y, et al. The effect of Bcl-2 gene silencing on the sensitivity of cell line A549 to chemotherapeutic drugs. Zhonghua Jie He He Hu Xi Za Zhi. 2013;36(3):191鈥? (in Chinese).PubMed
  68.Hu J, Jin W, Yang PM. Reversal of resistance to adriamycin in human breast cancer cell line MCF-7/ADM by beta-elemene. Zhonghua Zhong Liu Za Zhi. 2004;26(5):268鈥?0 (in Chinese).PubMed
  69.Li QQ, Lee RX, Liang H, Wang G, Li JM, Zhong Y, et al. beta-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK. Int J Oncol. 2013;43(3):721鈥?. doi:10.鈥?892/鈥媔jo.鈥?013.鈥?996 .PubMed Central PubMed
  70.Li QQ, Wang G, Liang H, Li JM, Huang F, Agarwal PK, et al. beta-Elemene promotes cisplatin-induced cell death in human bladder cancer and other carcinomas. Anticancer Res. 2013;33(4):1421鈥?.PubMed
  71.Li QQ, Wang G, Huang F, Li JM, Cuff CF, Reed E. Sensitization of lung cancer cells to cisplatin by beta-elemene is mediated through blockade of cell cycle progression: antitumor efficacies of beta-elemene and its synthetic analogs. Med Oncol. 2013;30(1):488. doi:10.鈥?007/鈥媠12032-013-0488-9 .CrossRef PubMed
  72.Ward A, Shukla K, Balwierz A, Soons Z, Konig R, Sahin O, et al. microRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumor-suppressor genes in ER+ breast cancer. J Pathol. 2014;. doi:10.鈥?002/鈥媝ath.鈥?363 .
  73.Zhang B, Zhang X, Tang B, Zheng P, Zhang Y. Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor alpha (ERalpha) re-expression. Breast Cancer Res Treat. 2012;136(2):399鈥?06. doi:10.鈥?007/鈥媠10549-012-2263-6 .CrossRef PubMed
  74.Wang Z, Xia Q, Cui J, Diao Y, Li J. Reversion of P-glycoprotein-mediated multidrug resistance by diallyl trisulfide in a human osteosarcoma cell line. Oncol Rep. 2014;31(6):2720鈥?. doi:10.鈥?892/鈥媜r.鈥?014.鈥?154 .PubMed
  75.Fu TH, Li JY, Jing YY, Sun PJ, Bai X. Effect of elemene on reversing chemoresistance to adriamycin in human stomach cancer cell line. Zhong Yao Cai. 2013;36(4):601鈥? (in Chinese).PubMed
  76.Zhu TZ, Li XM, Luo LH, Song ZQ, Gao X, Li ZQ, et al. beta-Elemene inhibits stemness, promotes differentiation and impairs chemoresistance to temozolomide in glioblastoma stem-like cells. Int J Oncol. 2014;45(2):699鈥?09. doi:10.鈥?892/鈥媔jo.鈥?014.鈥?448 .PubMed
  77.Zhu TZ, Li XM, Luo LH, Xu YH, Cao P, Liu Y, et al. beta-Elemene inhibits proliferation through crosstalk between glia maturation factor beta and extracellular signalregulated kinase 1/2 and impairs drug resistance to temozolomide in glioblastoma cells. Mol Med Rep. 2014;10(2):1122鈥?. doi:10.鈥?892/鈥媘mr.鈥?014.鈥?273 .PubMed
  78.Cai DY, Gao X, Wu XH, Hong TT. Synergistic effect of beta-elemene injection combined paclitaxel injection on human breast cancer MB-468 cells: an in vitro study. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013;33(7):978鈥?2 (in Chinese).PubMed
  79.Zhang F, Xu L, Qu X, Zhao M, Jin B, Kang J, et al. Synergistic antitumor effect of beta-elemene and etoposide is mediated via induction of cell apoptosis and cell cycle arrest in non-small cell lung carcinoma cells. Mol Med Rep. 2011;4(6):1189鈥?3. doi:10.鈥?892/鈥媘mr.鈥?011.鈥?37 .PubMed
  
• 作者单位：Guan-Nan Zhang (1)
  Charles R. Ashby Jr. (1)
  Yun-Kai Zhang (1)
  Zhe-Sheng Chen (1)
  Huiqin Guo (2)
  
  1. Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John鈥檚 University, Queens, NY, 11439, USA
  2. Department of Thoracic Surgery, Peking Union Medical College Hospital, Beijing, 100730, P. R. China
  
• 刊物类别：Oncology;
• 刊物主题：Oncology;
• 出版者：BioMed Central
• ISSN：1944-446X

文摘

Multidrug resistance (MDR), defined as the resistance of cancer cells to compounds with diverse structures and mechanisms of actions, significantly limits the efficacy of antitumor drugs. A major mechanism that mediates MDR in cancer is the overexpression of adenosine triphosphate (ATP)-binding cassette transporters. These transporters bind to their respective substrates and catalyze their efflux from cancer cells, thereby lowering the intracellular concentrations of the substrates and thus attenuating or even abolishing their efficacy. In addition, cancer cells can become resistant to drugs via mechanisms that attenuate apoptosis and cell cycle arrest such as alterations in the p53, check point kinase, nuclear factor kappa B, and the p38 mitogen-activated protein kinase pathway. In this review, we discuss the mechanisms by which 尾-elemene, a compound extracted from Rhizoma zedoariae that has clinical antitumor efficacy, overcomes drug resistance in cancer. Keywords Rhizoma zedoariae 尾-Elemene Multidrug resistance